<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027897</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00016181a</org_study_id>
    <secondary_id>DORICPK4003</secondary_id>
    <nct_id>NCT01027897</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients</brief_title>
  <official_title>Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients With Sepsis at Grady Health System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho-McNeil Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is to measure how the drug doripenem is cleared from the body of
      critically ill trauma patients. The investigators will measure blood drug concentrations and
      calculate how much the drug distributes in the body and how fast it is removed from the body.
      There is little information on how drugs are cleared in critically ill patients and the wrong
      dose of a drug could make it ineffective. The investigators will use this information to
      predict the most reasonable dose to treat infections effectively in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Understanding the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of an antibiotic
      can provide insight into developing appropriate dosing regimens. It is even more imperative
      at the present time to maximize PK/PD parameters since there are no new novel antimicrobial
      agents to treat resistant gram-negative infections. This approach allows us to achieve
      superior PD parameters and treat bacteria that would have been resistant to standard dosing
      due to higher minimum inhibitory concentrations (MICs).

      Doripenem exhibits time-dependent bactericidal activity and the pharmacodynamic parameter
      predicting clinical and bacteriologic outcomes is the percentage of the dosing interval that
      free drug concentrations remain above the minimum inhibitory concentration (T &gt; MIC) of the
      infecting pathogen Sepsis is known to influence drug pharmacokinetics and pharmacodynamics as
      a result of changes in hemodynamics, capillary permeability, third spacing, acid-base status,
      serum proteins, and organ function. Moreover, trauma patients tend to be younger with fewer
      comorbidities. They are hypermetabolic and are often given aggressive fluid resuscitation
      resulting in increased renal clearance of drugs and a larger volume of distribution. As a
      consequence of these differences in PK parameters, the calculated PD parameters will likely
      differ resulting in sub-optimal T&gt; MIC. For time-dependent antibacterial agents such as
      doripenem, the T &gt; MIC is one of the most important pharmacodynamic parameters in predicting
      clinical efficacy, therefore it is imperative to evaluate the PK parameters in this
      particular population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of Distribution (Vd)</measure>
    <time_frame>After 3rd dose of study medication</time_frame>
    <description>The Volume of distribution is the calculated volume that the given amount of drug is uniformly distributed in the body to achieve a particular concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>After 3rd dose of study medication</time_frame>
    <description>Clearance is the volume of drug removed from the body per unit of time (hrs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Constant (ke)</measure>
    <time_frame>after 3rd dose of study drug</time_frame>
    <description>The elimination rate constant of a drug from the central compartment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Doripenem group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive doripenem for the treatment of their infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doripenem</intervention_name>
    <description>Doripenem 1 gm administered over 4 hours X 3 doses</description>
    <arm_group_label>Doripenem group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients are 18 years of age or older

          -  Admitted to Emory surgical intensive care unit (ICU) service

          -  Have a diagnosis of sepsis that requires empiric antimicrobial therapy

          -  Obtained written informed consent from the patient or a first-degree relative if the
             patient is unable to give informed consent due to his/her medical condition prior to
             initiation of any study procedure

        Exclusion Criteria:

          -  Surgical ICU length of stay less than 24 hours

          -  Acute or chronic renal dysfunction (urine output less than 0.5 mL/kg/hr or calculated
             creatinine clearance of less than 50 mL/min)

          -  Pregnancy

          -  Known allergy to beta-lactam antibiotics

          -  Non-English-speaking patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Salomone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <results_first_submitted>April 5, 2012</results_first_submitted>
  <results_first_submitted_qc>August 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2012</results_first_posted>
  <last_update_submitted>December 19, 2013</last_update_submitted>
  <last_update_submitted_qc>December 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Doripenem</keyword>
  <keyword>Trauma</keyword>
  <keyword>sepsis</keyword>
  <keyword>Trauma patients with sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from April 2010 to July 2011. All patients were admitted to the Surgical ICU during the study period</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Doripenem Group</title>
          <description>Patients will receive doripenem 1 gm IV over 4 hours X 3 doses for the empiric treatment of an infection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doripenem Group</title>
          <description>Patients will receive doripenem 1 gm IV over 4 hours X 3 doses for the empiric treatment of an infection</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution (Vd)</title>
        <description>The Volume of distribution is the calculated volume that the given amount of drug is uniformly distributed in the body to achieve a particular concentration</description>
        <time_frame>After 3rd dose of study medication</time_frame>
        <population>Patients that completed the study and did not have atypical variations in the measurement of serum concentrations were included in the final evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>Doripenem Group</title>
            <description>Patients will receive doripenem 1 gm IV over 4 hours X 3 doses for the empiric treatment of an infection</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vd)</title>
          <description>The Volume of distribution is the calculated volume that the given amount of drug is uniformly distributed in the body to achieve a particular concentration</description>
          <population>Patients that completed the study and did not have atypical variations in the measurement of serum concentrations were included in the final evaluation</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.52" spread="16.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clearance (CL)</title>
        <description>Clearance is the volume of drug removed from the body per unit of time (hrs).</description>
        <time_frame>After 3rd dose of study medication</time_frame>
        <population>Patients that completed the study and did not have atypical variations in the measurement of serum concentrations were included in the final evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>Doripenem Group</title>
            <description>Patients will receive doripenem 1 gm IV over 4 hours X 3 doses for the empiric treatment of an infection</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL)</title>
          <description>Clearance is the volume of drug removed from the body per unit of time (hrs).</description>
          <population>Patients that completed the study and did not have atypical variations in the measurement of serum concentrations were included in the final evaluation</population>
          <units>liters per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.94" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elimination Constant (ke)</title>
        <description>The elimination rate constant of a drug from the central compartment</description>
        <time_frame>after 3rd dose of study drug</time_frame>
        <population>Patients that completed the study and did not have atypical variations in the measurement of serum concentrations were included in the final evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>Doripenem Group</title>
            <description>Patients will receive doripenem 1 gm IV over 4 hours X 3 doses for the empiric treatment of an infection</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Constant (ke)</title>
          <description>The elimination rate constant of a drug from the central compartment</description>
          <population>Patients that completed the study and did not have atypical variations in the measurement of serum concentrations were included in the final evaluation</population>
          <units>per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Doripenem Group</title>
          <description>Patients will receive doripenem 1 gm IV over 4 hours X 3 doses for the empiric treatment of an infection</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <description>Not related to drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <description>Not related to drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower gastrointestinal</sub_title>
                <description>Not related to drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure acute</sub_title>
                <description>Not related to drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Post operative wound</sub_title>
                <description>post operative wound infection. Not related to drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <description>Doubtful if related to drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prasad Abraham</name_or_title>
      <organization>Grady Health System</organization>
      <phone>404-616-3246</phone>
      <email>pabraham@gmh.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

